Evidence map›Paper›PMID 34140458›Full record

ArticleClinical and translational gastroenterology2021

Detection of Postcolonoscopy Colorectal Neoplasia by Multi-target Stool DNA.

Derek W Ebner, Jason D Eckmann, Kelli N Burger, Douglas W Mahoney, Jamie Bering, Allon Kahn, Eduardo A Rodriguez, David O Prichard, Michael B Wallace, Sunanda V Kane and 3 more

Abstract read
In one paragraph

Article in Clinical and translational gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Derek W EbnerDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Jason D EckmannDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Kelli N BurgerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Douglas W MahoneyDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Jamie BeringDivision of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA.
Allon KahnDivision of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA.
Eduardo A RodriguezDivision of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA.
David O PrichardDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Michael B WallaceDivision of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
Sunanda V KaneDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Lila J Finney RuttenDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Suryakanth R GuruduDivision of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA.
John B KisielDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-3840-5324

Funding

Multi-site Gastrointestinal Cancer Detection by Stool DNA MethylationR37CA214679 · NCI · MAYO CLINIC ROCHESTER · PI KISIEL, JOHN · 2018 to 2024
$2.8M
Multi-cancer Early DetectionR01CA214679 · NCI · MAYO CLINIC ROCHESTER · PI John Kisiel, Niloy Jewel Samadder · 2025 to 2026
$891k
NCI NIH HHS R01 CA214679NCI NIH HHS R37 CA214679
6 · The paper itself

Abstract

introductionSignificant variability between colonoscopy operators contributes to postcolonoscopy colorectal cancers (CRCs). We aimed to estimate postcolonoscopy colorectal neoplasia (CRN) detection by multi-target stool DNA (mt-sDNA), which has not previously been studied for this purpose.

methodsIn a retrospective cohort of patients with +mt-sDNA and completed follow-up colonoscopy, positive predictive value (PPV) for endpoints of any CRN, advanced adenoma, right-sided neoplasia, sessile serrated polyps (SSP), and CRC were stratified by the time since previous colonoscopy (0-9, 10, and ≥11 years). mt-sDNA PPV at ≤9 years from previous average-risk screening colonoscopy was used to estimate CRN missed at previous screening colonoscopy.

resultsAmong the 850 studied patients with +mt-sDNA after a previous negative screening colonoscopy, any CRN was found in 535 (PPV 63%). Among 107 average-risk patients having +mt-sDNA ≤9 years after last negative colonoscopy, any CRN was found in 67 (PPV 63%), advanced neoplasia in 16 (PPV 15%), right-sided CRN in 48 (PPV 46%), and SSP in 20 (PPV 19%). These rates were similar to those in 47 additional average risk persons with previous incomplete colonoscopy and in an additional 68 persons at increased CRC risk. One CRC (stage I) was found in an average risk patient who was mt-sDNA positive 6 years after negative screening colonoscopy. DISCUSSION: The high PPV of mt-sDNA 0-9 years after a negative screening colonoscopy suggests that lesions were likely missed on previous examination or may have arisen de novo. mt-sDNA as an interval test after negative screening colonoscopy warrants further study.

Indexed as

ColonoscopyAdenomaAgedColorectal NeoplasmsDNA, NeoplasmEarly Detection of CancerFecesFemaleHumansMaleMass ScreeningMiddle AgedPrecancerous ConditionsPredictive Value of TestsRetrospective StudiesDNA, Neoplasm

Identifiers

PMID34140458
PMCPMC8216679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.